The FDA’s Proposed Rule on Laboratory-Developed Tests: Impacts on Clinical Laboratory Testing and Patient Care

Leslie Smith, Lisa A. Carricaburu, Jonathan R. Genzen
doi: https://doi.org/10.1101/2024.02.28.24303459

Article Information

doi 
https://doi.org/10.1101/2024.02.28.24303459
History 
  • March 1, 2024.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Leslie Smith1,
  2. Lisa A. Carricaburu1 and
  3. Jonathan R. Genzen1,2,*
  1. 1ARUP Laboratories, Salt Lake City, UT, United States of America
  2. 2Department of Pathology, University of Utah Health, Salt Lake City, UT, United States of America
  1. ↵*Corresponding Author, Email: jonathan.genzen{at}path.utah.edu
Back to top
Posted March 01, 2024.
Download PDF
Data/Code
Email
The FDA’s Proposed Rule on Laboratory-Developed Tests: Impacts on Clinical Laboratory Testing and Patient Care
Leslie Smith, Lisa A. Carricaburu, Jonathan R. Genzen
medRxiv 2024.02.28.24303459; doi: https://doi.org/10.1101/2024.02.28.24303459
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area